{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:25:58Z","timestamp":1790641558228,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82350102"],"award-info":[{"award-number":["82350102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Key Research & Development Plan of Jiangsu Province","award":["BE2022711"],"award-info":[{"award-number":["BE2022711"]}]},{"name":"the Xuzhou Medical leading talents Training program","award":["XWRCHT20210028"],"award-info":[{"award-number":["XWRCHT20210028"]}]},{"name":"the Xuzhou medical science and technology innovation project","award":["XWKYHT20230070"],"award-info":[{"award-number":["XWKYHT20230070"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04503-4","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:43:54Z","timestamp":1746060234000},"page":"3439-3449","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma"],"prefix":"10.1007","volume":"57","author":[{"given":"Zihan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yegan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunming","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"issue":"10272","key":"4503_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/s0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL (2021) Multiple myeloma. Lancet 397(10272):410\u2013427. https:\/\/doi.org\/10.1016\/s0140-6736(21)00135-5","journal-title":"Lancet"},{"issue":"11","key":"4503_CR2","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","volume":"31","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H et al (2017) Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia 31(11):2443\u20132448. https:\/\/doi.org\/10.1038\/leu.2017.138","journal-title":"Leukemia"},{"issue":"12","key":"4503_CR3","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/jco.2016.71.1663","volume":"35","author":"CHY van Beurden-Tan","year":"2017","unstructured":"van Beurden-Tan CHY, Franken MG, Blommestein HM, Uyl-de Groot CA, Sonneveld P (2017) Systematic literature review and network meta-analysis of treatment outcomes in relapsed and\/or refractory multiple myeloma. J Clin Oncol 35(12):1312\u20131319. https:\/\/doi.org\/10.1200\/jco.2016.71.1663","journal-title":"J Clin Oncol"},{"issue":"8","key":"4503_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","volume":"127","author":"C Touzeau","year":"2016","unstructured":"Touzeau C, Moreau P (2016) How I treat extramedullary myeloma. Blood 127(8):971\u2013976. https:\/\/doi.org\/10.1182\/blood-2015-07-635383","journal-title":"Blood"},{"issue":"8","key":"4503_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384(8):705\u2013716. https:\/\/doi.org\/10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"issue":"11","key":"4503_CR6","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/jco.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A et al (2023) Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T Consortium. J Clin Oncol 41(11):2087\u20132097. https:\/\/doi.org\/10.1200\/jco.22.01365","journal-title":"J Clin Oncol"},{"issue":"10297","key":"4503_CR7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/s0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398(10297):314\u2013324. https:\/\/doi.org\/10.1016\/s0140-6736(21)00933-8","journal-title":"Lancet"},{"issue":"6","key":"4503_CR8","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/jco.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P et al (2023) Ciltacabtagene Autoleucel, an Anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol 41(6):1265\u20131274. https:\/\/doi.org\/10.1200\/jco.22.00842","journal-title":"J Clin Oncol"},{"issue":"2","key":"4503_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188\u2013195. https:\/\/doi.org\/10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"issue":"26","key":"4503_CR10","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127(26):3321\u20133330. https:\/\/doi.org\/10.1182\/blood-2016-04-703751","journal-title":"Blood"},{"issue":"1","key":"4503_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL et al (2018) Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.148","journal-title":"Nat Rev Clin Oncol"},{"issue":"21","key":"4503_CR12","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130(21):2295\u20132306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141","journal-title":"Blood"},{"issue":"12","key":"4503_CR13","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.Cd-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF et al (2017) Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T Cells. Cancer Discov 7(12):1404\u20131419. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0698","journal-title":"Cancer Discov"},{"issue":"6","key":"4503_CR14","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","volume":"26","author":"V Gutgarts","year":"2020","unstructured":"Gutgarts V, Jain T, Zheng J, Maloy MA, Ruiz JD, Pennisi M et al (2020) Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery. Biol Blood Marrow Transpl 26(6):1071\u20131076. https:\/\/doi.org\/10.1016\/j.bbmt.2020.02.012","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"4503_CR15","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1053\/j.ajkd.2020.08.017","volume":"77","author":"MD Lee","year":"2021","unstructured":"Lee MD, Strohbehn IA, Seethapathy HS, Rusibamayila N, Casey KS, Gupta S et al (2021) Acute kidney injury after the CAR-T therapy tisagenlecleucel. Am J Kidney Dis 77(6):990\u2013992. https:\/\/doi.org\/10.1053\/j.ajkd.2020.08.017","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"4503_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","volume":"76","author":"S Gupta","year":"2020","unstructured":"Gupta S, Seethapathy H, Strohbehn IA, Frigault MJ, O\u2019Donnell EK, Jacobson CA et al (2020) Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-Cell lymphoma. Am J Kidney Dis 76(1):63\u201371. https:\/\/doi.org\/10.1053\/j.ajkd.2019.10.011","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"4503_CR17","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.mayocp.2022.05.018","volume":"97","author":"N Farooqui","year":"2022","unstructured":"Farooqui N, Sy-Go JPT, Miao J, Mehta R, Vaughan LE, Bennani NN et al (2022) Incidence and risk factors for acute kidney injury after chimeric antigen receptor T-Cell therapy. Mayo Clin Proc 97(7):1294\u20131304. https:\/\/doi.org\/10.1016\/j.mayocp.2022.05.018","journal-title":"Mayo Clin Proc"},{"issue":"29","key":"4503_CR18","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/jco.21.02614","volume":"40","author":"M D'Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A et al (2022) Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a european myeloma network (EMN) report Within the HARMONY project. J Clin Oncol 40(29):3406\u20133418. https:\/\/doi.org\/10.1200\/jco.21.02614","journal-title":"J Clin Oncol"},{"issue":"4","key":"4503_CR19","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120(4):c179-184. https:\/\/doi.org\/10.1159\/000339789","journal-title":"Nephron Clin Pract"},{"issue":"13","key":"4503_CR20","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/jco.2015.65.0044","volume":"34","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E et al (2016) International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 34(13):1544\u20131557. https:\/\/doi.org\/10.1200\/jco.2015.65.0044","journal-title":"J Clin Oncol"},{"issue":"4s","key":"4503_CR21","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"KDIGO","year":"2024","unstructured":"KDIGO (2024) Clinical practice guideline for the evaluation and management of chronic kidney disease (2024). Kidney Int 105(4s):S117-s314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"issue":"4","key":"4503_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl 25(4):625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transpl"},{"key":"4503_CR23","unstructured":"[Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines] (2004). Int J Clin Oncol 9 Suppl 3:1\u201382"},{"issue":"8","key":"4503_CR24","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"issue":"11","key":"4503_CR25","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1038\/s41409-020-0930-5","volume":"55","author":"H Li","year":"2020","unstructured":"Li H, Yin L, Wang Y, Wang X, Shi M, Cao J et al (2020) Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma with renal impairment. Bone Marrow Transpl 55(11):2215\u20132218. https:\/\/doi.org\/10.1038\/s41409-020-0930-5","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"4503_CR26","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/s2352-3026(19)30115-2","volume":"6","author":"Z Yan","year":"2019","unstructured":"Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y et al (2019) A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol 6(10):e521\u2013e529. https:\/\/doi.org\/10.1016\/s2352-3026(19)30115-2","journal-title":"Lancet Haematol"},{"issue":"20","key":"4503_CR27","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/jco.21.01676","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z et al (2022) Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma. J Clin Oncol 40(20):2246\u20132256. https:\/\/doi.org\/10.1200\/jco.21.01676","journal-title":"J Clin Oncol"},{"issue":"14","key":"4503_CR28","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1200\/jco.22.01824","volume":"41","author":"J Xia","year":"2023","unstructured":"Xia J, Li H, Yan Z, Zhou D, Wang Y, Qi Y et al (2023) Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm Phase II Trial. J Clin Oncol 41(14):2583\u20132593. https:\/\/doi.org\/10.1200\/jco.22.01824","journal-title":"J Clin Oncol"},{"issue":"1","key":"4503_CR29","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","volume":"15","author":"M Shi","year":"2024","unstructured":"Shi M, Wang J, Huang H, Liu D, Cheng H, Wang X et al (2024) Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial. Nat Commun 15(1):3371. https:\/\/doi.org\/10.1038\/s41467-024-47801-8","journal-title":"Nat Commun"},{"issue":"10","key":"4503_CR30","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1016\/s2352-3026(24)00176-5","volume":"11","author":"D Zhou","year":"2024","unstructured":"Zhou D, Sun Q, Xia J, Gu W, Qian J, Zhuang W et al (2024) Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial. Lancet Haematol 11(10):e751\u2013e760. https:\/\/doi.org\/10.1016\/s2352-3026(24)00176-5","journal-title":"Lancet Haematol"},{"issue":"19","key":"4503_CR31","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1056\/NEJMra0904569","volume":"364","author":"SC Howard","year":"2011","unstructured":"Howard SC, Jones DP, Pui CH (2011) The tumor lysis syndrome. N Engl J Med 364(19):1844\u20131854. https:\/\/doi.org\/10.1056\/NEJMra0904569","journal-title":"N Engl J Med"},{"issue":"23","key":"4503_CR32","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum DC, June CH (2020) Cytokine Storm. N Engl J Med 383(23):2255\u20132273. https:\/\/doi.org\/10.1056\/NEJMra2026131","journal-title":"N Engl J Med"},{"issue":"7","key":"4503_CR33","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.2215\/cjn.02210218","volume":"13","author":"SM Norby","year":"2018","unstructured":"Norby SM (2018) Requirements for procedural skills in nephrology training programs: framing the conversation. Clin J Am Soc Nephrol 13(7):1096\u20131098. https:\/\/doi.org\/10.2215\/cjn.02210218","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"4503_CR34","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.ekir.2021.03.012","volume":"6","author":"A Batte","year":"2021","unstructured":"Batte A, Menon S, Opika RO, Kiguli S, Kalyesubula R, Leigh AC (2021) Pos-006 acute kidney injury among children with sickle cell anemia hospitalised with vaso-occlusion in Uganda. Kidney Int Rep 6(4):S2\u2013S3. https:\/\/doi.org\/10.1016\/j.ekir.2021.03.012","journal-title":"Kidney Int Rep"},{"issue":"Pt B","key":"4503_CR35","doi-asserted-by":"publisher","first-page":"107072","DOI":"10.1016\/j.intimp.2020.107072","volume":"89","author":"H Zhou","year":"2020","unstructured":"Zhou H, Yang M, Cui L, Jiang J (2020) Chimeric antigen receptor T cell therapy and nephrotoxicity: from diagnosis to treatment strategies. Int Immunopharmacol 89(Pt B):107072. https:\/\/doi.org\/10.1016\/j.intimp.2020.107072","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"4503_CR36","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.immuni.2019.03.020","volume":"50","author":"W Ouyang","year":"2019","unstructured":"Ouyang W, O\u2019Garra A (2019) IL-10 Family Cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity 50(4):871\u2013891. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.020","journal-title":"Immunity"},{"issue":"4","key":"4503_CR37","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.immuni.2019.03.022","volume":"50","author":"M Dougan","year":"2019","unstructured":"Dougan M, Dranoff G, Dougan SK (2019) GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation. Immunity 50(4):796\u2013811. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.022","journal-title":"Immunity"},{"issue":"10","key":"4503_CR38","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.2215\/cjn.04970512","volume":"7","author":"AW Williams","year":"2012","unstructured":"Williams AW, Dwyer AC, Eddy AA, Fink JC, Jaber BL, Linas SL et al (2012) Critical and honest conversations: the evidence behind the \u201cChoosing Wisely\u201d campaign recommendations by the American Society of Nephrology. Clin J Am Soc Nephrol 7(10):1664\u20131672. https:\/\/doi.org\/10.2215\/cjn.04970512","journal-title":"Clin J Am Soc Nephrol"},{"key":"4503_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-94-017-7215-0_8","volume":"867","author":"V Jurisic","year":"2015","unstructured":"Jurisic V, Radenkovic S, Konjevic G (2015) The actual role of LDH as tumor marker, biochemical and clinical aspects. Adv Exp Med Biol 867:115\u2013124. https:\/\/doi.org\/10.1007\/978-94-017-7215-0_8","journal-title":"Adv Exp Med Biol"},{"issue":"11","key":"4503_CR40","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.clml.2022.07.007","volume":"22","author":"G Ahmed","year":"2022","unstructured":"Ahmed G, Bhasin-Chhabra B, Szabo A, Shah NN, Longo W, Dhakal B et al (2022) Impact of chronic kidney disease and acute kidney injury on safety and outcomes of CAR T-cell therapy in lymphoma patients. Clin Lymphoma Myeloma Leuk 22(11):863\u2013868. https:\/\/doi.org\/10.1016\/j.clml.2022.07.007","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04503-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04503-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04503-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:00:14Z","timestamp":1758808814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04503-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["4503"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04503-4","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}